The eveRA phase 3 trial presented at #ESMO25 by @elmayermd : oral SERD Giredestrant + Everolimus improved INV-PFS vs SOC endocrine therapy + Everolimus post-CDK4/6i in metastatic HR+/HER2- MBC: 🔹ESR1m population: 9.99 vs 5.54 mo 🔹ITT population: 8.77 vs 5.49 mo @OncoAlert

Fantastic highlights of the diff between #ASCENT03 and #TB02 In TB-02: 📍poorer prognosis pts, 15% relapsed within 6 mo of neoadj/adj thpy 📍no doublet chemo 📍no crossover to ADC 📍dato didn't look to have OS in areas where there wasTROP2 ADC access #ESMO25 #ESMOAmbassadors

#ESMO25 Pegfilgrastim timing matters! In this randomized phase III trial (n=159, early-stage BC): Giving pegfilgrastim 72h after chemo — instead of 24–48h — cut bone pain by >50% without increasing neutropenia or FN risk.

Breaking: HER2CLIMB-05 Pfizer reports positive Phase 3 results — adding TUKYSA (tucatinib) to trastuzumab + pertuzumab maintenance significantly improves PFS in first-line HER2+ metastatic breast cancer. 🔹 Trial: HER2CLIMB-05 🔹 Setting: 1L maintenance after chemo + HP 🔹

DESTINY-Breast11 #ESMO25 🧬 Neoadjuvant T-DXd-THP vs ddAC-THP in high-risk HER2+ eBC: pCR 67.3 vs 56.3 % (+11.2%, p = 0.003) Grade ≥3 AE 37.5 vs 55.8 % LVEF 1.9 vs 9 % ILD 4.4 vs 5.1 % Early EFS HR 0.56 (immature). ➡️ Better efficacy + safety, anthracycline-free option. But pCR

Follow-up results from the POSITIVE Trial regarding breastfeeding after hormone receptor-positive #BreastCancer show no differences in breast cancer related events in women who breastfed compared with those who did not. 👉 https://t.co/uLN0VUBKyp @fedrophd @AnnPartridgeMD

Wish that this trial had included a fulvestrant/everolimus arm, rather than randomizing 131 patients to fulvestrant monotherapy.

What an incredible #ASCO25! We were thrilled to connect with everyone who came through our booth and want to thank the Naterans on our team for their hard work in making it a special event. Thank you to Marla Lipsyc-Sharf, MD, Julia Foldi, MD, PhD and Mridula George, MD

Major unmet need for Mutant Specific PIK3CA inhibitors with improved efficacy and side effects for our patients. RLY2608 + Fulvestrant in post-CDK4/6 HR+, HER2- PIK3CA mutant breast cancer. ORR close to 40% post-CDK4/6. Median PFS 10 months all comers, 11 months 2L, 18 months

.@AngieDemichele 🔥🔥🔥 #ASCO25 FANTASTIC discussion. Yes to all of this. 🎯

Here is the study where these figures are quoted. Flatiron Database which is mostly community oncology centers around the US.

Busy morning 🎬 with @OncLive It was great to represent @MDAndersonNews and our #MDACC_BMO_Department Session #1 was information packed about #ESR1m and the evolving treatment landscape Session #2 was a panel discussion about the expanding field of ctDNA/MRD testing in

Dr Sonya Reid makes excellent point in Metastatic TNBC Sadly 50% of patients do not make it to second line therapy in mTNBC. In that case, waiting beyond first line to give a more effective regimen seems silly. #bcsm #ASCO25

Real world data suggest that chemo (cape, eribulin, taxanes) outperforms a second topo1 ADC after progression on T-DXd. Key question to address in breast oncology (and across oncology fields!). #ESMOBreast25 #esmoambassadors

Check out this recent @Annals_Oncology #ctDNA review and meta-analysis👉Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors. 👉 https://t.co/R2Y5LIt9ir

3rd positive Press release in <3 weeks: DB11 achieved positive results, with neoadjuvant T-DXd->THP improving pCR rates over AC-THP in high-risk HER2+ BC. Many open questions. But, overall, great optimism. And a reinforced certainty: 2025 will be #ADCYear. https://t.co/0kiUebLhF5

Fantastic talk answering the question “Which tumors warrant adjuvant CDK4/6 inhibitors?” Here are the 🔑 take aways from @AngieDemichele (which I was really thankful for, as I otherwise took photos of every slide 😅) #SGBCC2025

🔑 summaries from @Prof_Nadia_H at @SG_BCC #SGBCC2025

Excellent discussion by @KalinskyKevin about if there is a need for chemotherapy in premenopausal pts Chemo recommended: Regardless of age if RS>30 If≤50, RS>21 (RSClin can help ) Postmenopausal: 2+ LN + high risk fx + ≥4LN @SG_BCC #bcsm

What mediates resistance to antibody drug conjugates? Report @CCR_AACR shows that in pts with breast cancer treated with trastuzumab deruxtecan (T-DXd, #HER2 ADC), 32% lost HER2 expression by IHC and another 29% had a decrease in HER2 score. https://t.co/JBAERsfglz